# Moleculin Total Asset

MBRX | Stock | ## USD 1.75 0.07 4.17% |

Moleculin Biotech CS fundamentals help investors to digest information that contributes to Moleculin Biotech's financial success or failures. It also enables traders to predict the movement of Moleculin Stock. The fundamental analysis module provides a way to measure Moleculin Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Moleculin Biotech stock.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Moleculin | Total Asset |

**M**in 2022. Total Assets Per Share is likely to rise to 3.74 in 2022.

## Moleculin Total Asset Analysis

Moleculin Biotech's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value. 2021 | 2022 (projected) | |

Accounts Payable | 1.36 M | 1.2 M |

Receivables | 23 K | 24.82 K |

Total Asset | = | Tangible Assets | + | Intangible Assets |

## Current Moleculin Biotech Total Asset | 28.09 K |

Most of Moleculin Biotech's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Moleculin Biotech CS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

## Moleculin Total Asset Driver Correlations

Understanding the fundamental principles of building solid financial models for Moleculin Biotech is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Total Asset. Since Moleculin Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Moleculin Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Moleculin Biotech's interrelated accounts and indicators.

## Moleculin Total Asset Historical Pattern

Today, most investors in Moleculin Biotech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Moleculin Biotech's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Moleculin Biotech total asset as a starting point in their analysis.

Moleculin Biotech Total Asset |

Share

Timeline |

Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.

Compare to competition |

## Moleculin Total Assets

## Total Assets | ## 90.73 Million |

Based on the latest financial disclosure, Moleculin Biotech CS has a Total Asset of 28.09

**K**. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The total asset for all United States stocks is 100.0% higher than that of the company.## Moleculin Biotech Current Valuation Drivers

We derive many important indicators used in calculating different scores of Moleculin Biotech from analyzing Moleculin Biotech's financial statements. These drivers represent accounts that assess Moleculin Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Moleculin Biotech's important valuation drivers and their relationship over time.

2017 | 2018 | 2019 | 2020 | 2021 | 2022 (projected) | ||

Net Income Per Employee | (1.23 M) | (913.54 K) | (825.31 K) | (1.15 M) | (934.94 K) | (1.01 M) | |

Average Assets | 20.42 M | 22.37 M | 27.2 M | 28.26 M | 91.53 M | 98.75 M | |

Earnings Before Interest Taxes and Depreciation Amortization EBITDA | (9.79 M) | (11.81 M) | (13.23 M) | (17.16 M) | (15.73 M) | (16.14 M) | |

Earnings Before Interest Taxes and Depreciation Amortization USD | (9.79 M) | (11.81 M) | (13.23 M) | (17.16 M) | (15.73 M) | (16.14 M) | |

Earnings before Tax | (9.8 M) | (11.88 M) | (13.43 M) | (17.36 M) | (15.89 M) | (16.31 M) | |

Average Equity | 17.8 M | 16.64 M | 17.83 M | 15.79 M | 83.37 M | 89.95 M | |

Enterprise Value | 30.58 M | 19.61 M | 26.74 M | 37.19 M | (21.95 M) | (22.53 M) | |

Free Cash Flow | (7.35 M) | (12.62 M) | (17.25 M) | (18.14 M) | (18.97 M) | (19.47 M) | |

Invested Capital | (1.59 M) | (2.58 M) | 58 K | (51 K) | (1.52 M) | (1.56 M) | |

Invested Capital Average | (1.37 M) | (2.15 M) | (4.8 M) | (107.75 K) | (1.3 M) | (1.41 M) | |

Market Capitalization | 39.31 M | 28.21 M | 41.85 M | 49.79 M | 53.15 M | 51.11 M | |

Tangible Asset Value | 8.34 M | 8.44 M | 14.09 M | 17.88 M | 72.94 M | 78.7 M | |

Working Capital | 6.09 M | 4.1 M | 9.91 M | 14.28 M | 68.88 M | 74.31 M |

## Moleculin Fundamentals

Return On Equity | (22.73) % | |||

Return On Asset | (16.77) % | |||

Current Valuation | (17.68 M) | |||

Shares Outstanding | 28.58 M | |||

Shares Owned by Insiders | 2.33 % | |||

Shares Owned by Institutions | 14.36 % | |||

Number of Shares Shorted | 118.17 K | |||

Price to Earning | (3.81) X | |||

Price to Book | 0.60 X | |||

Price to Sales | 0.83 X | |||

EBITDA | (23.8 M) | |||

Net Income | (18.32 M) | |||

Cash and Equivalents | 66.1 M | |||

Cash per Share | 2.31 X | |||

Total Debt | 127 K | |||

Debt to Equity | 0.001 % | |||

Current Ratio | 13.91 X | |||

Book Value Per Share | 2.84 X | |||

Cash Flow from Operations | (20.13 M) | |||

Short Ratio | 3.09 X | |||

Earnings Per Share | (0.70) X | |||

Number of Employees | 13 | |||

Beta | 1.8 | |||

Market Capitalization | 48.58 M | |||

Total Asset | 28.09 K | |||

Retained Earnings | (40.6 M) | |||

Working Capital | (744.7 K) | |||

Current Asset | 28.09 K | |||

Current Liabilities | 772.79 K |

## About Moleculin Biotech Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Moleculin Biotech CS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Moleculin Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Moleculin Biotech CS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.Last Reported | Projected for 2022 | |

Total Assets | 84.1 M | 90.7 M |

Total Assets Per Share | 2.94 | 3.74 |

Net Current Assets as percentage of Total Assets | 81.91 | 88.37 |

Average Assets | 91.5 M | 98.8 M |

Tangible Asset Value | 72.9 M | 78.7 M |

## Moleculin Biotech Investors Sentiment

The influence of Moleculin Biotech's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Moleculin. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Moleculin Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Moleculin Biotech's short interest history, or implied volatility extrapolated from Moleculin Biotech options trading.

## Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Moleculin Biotech using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.## Build Optimal Portfolios

### Align your risk with return expectations

Additionally, see Moleculin Biotech Piotroski F Score and Moleculin Biotech Altman Z Score analysis. Note that the Moleculin Biotech information on this page should be used as a complementary analysis to other Moleculin Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.

## Complementary Tools for Moleculin Stock analysis

When running Moleculin Biotech price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.

Alpha FinderUse alpha and beta coefficients to find investment opportunities after accounting for the risk | Go | |

Risk-Return AnalysisView associations between returns expected from investment and the risk you assume | Go | |

Portfolio DiagnosticsUse generated alerts and portfolio events aggregator to diagnose current holdings | Go | |

Equity ForecastingUse basic forecasting models to generate price predictions and determine price momentum | Go | |

Efficient FrontierPlot and analyze your portfolio and positions against risk-return landscape of the market. | Go | |

ETF DirectoryFind actively traded Exchange Traded Funds (ETF) from around the world | Go | |

Pair CorrelationCompare performance and examine fundamental relationship between any two equity instruments | Go | |

Portfolio RebalancingAnalyze risk-adjusted returns against different time horizons to find asset-allocation targets | Go |

Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Market Capitalization 48 M | Return On Assets -0.17 | Return On Equity -0.23 |

The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Moleculin Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.